Surgical and Oncological Outcomes after Neoadjuvant Therapy for Non-Metastatic Gastric GISTs

[1]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[2]  P. Hohenberger,et al.  Neoadjuvant Therapy to Downstage the Extent of Resection of Gastrointestinal Stromal Tumors , 2018, Visceral Medicine.

[3]  P Reichardt,et al.  Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Blettner,et al.  Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany , 2018, BMC Public Health.

[5]  M. McCarter,et al.  Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  S. Hahn,et al.  Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach , 2017, British Journal of Cancer.

[7]  H. Gevensleben,et al.  Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events. , 2017, Human pathology.

[8]  B. Bjerkehagen,et al.  Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine , 2016, The British journal of surgery.

[9]  J. Blay,et al.  Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting. , 2016, European journal of cancer.

[10]  F. van Coevorden,et al.  Surgical Treatment of Gastrointestinal Stromal Tumors Located in the Stomach in the Imatinib Era , 2015, American journal of clinical oncology.

[11]  Seiichi Hirota,et al.  The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines , 2015, Gastric Cancer.

[12]  C. Fisher,et al.  Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib , 2015, The British journal of surgery.

[13]  E. Wardelmann,et al.  Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy , 2015, Expert review of anticancer therapy.

[14]  Heli Liu,et al.  Treatment strategy of rectal gastrointestinal stromal tumor (GIST) , 2014, Journal of surgical oncology.

[15]  F. van Coevorden,et al.  Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[16]  Xiao-wu Xu,et al.  GASTROINTESTINAL STROMAL TUMORS OF THE STOMACH , 2014 .

[17]  S. Sleijfer,et al.  Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience , 2013, Annals of Surgical Oncology.

[18]  J. Blay,et al.  Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group , 2014, BMC Cancer.

[19]  C. Mussi,et al.  Gastrointestinal Stromal Tumor of the Rectum: Results of Surgical and Multimodality Therapy in the Era of Imatinib , 2013, Annals of Surgical Oncology.

[20]  Aki Vehtari,et al.  Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. , 2012, The Lancet. Oncology.

[21]  Tae Won Kim,et al.  Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Blay,et al.  Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Demetri,et al.  Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665 , 2009, Journal of surgical oncology.

[24]  C. Antonescu,et al.  Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) , 2008, Cancer.

[25]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[27]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[28]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.